secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001628280-23-021025
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab partner Novocure's LUNAR Phase 3 trial meets endpoint, shows 3-month OS improvement in metastatic NSCLC
--------------------------------------------------------------------------------

- TTFields + standard therapies improved median OS from 9.9 to 13.2 months (HR 0.74, p=0.035) in post-platinum metastatic NSCLC.
- ICI subgroup median OS was 18.5 vs 10.8 months (HR 0.63, p=0.03), an 8-month improvement.
- TTFields was well-tolerated with no added systemic toxicities; only grade 3 device-related AEs.
- Novocure plans PMA submission to FDA in H2 2023; Zai Lab will file MAA to China's NMPA thereafter.
- Zai Lab has exclusive license to develop/commercialize TTFields in Greater China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023021025/0001628280-23-021025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023021025/zlab-20230606.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-021025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer